Dr. Lili Mao is an accomplished young expert in the fields of melanoma and genitourinary malignancies in China. She has long been dedicated to the clinical management and research of melanoma, renal cell carcinoma, urothelial carcinoma, and other genitourinary cancers. She previously conducted visiting studies at the Oncology Center of Westmead Hospital, University of Sydney, and at the Melanoma Institute Australia (MIA), gaining strong international clinical and research exposure.
Dr. Mao has extensive experience in targeted therapy, immunotherapy, and chemotherapy. She has led and participated in multiple national research projects, with a focus on the pathogenesis of melanoma, identification of molecular biomarkers, and the development of novel therapeutic strategies. Her work has contributed to the clinical translation and application of innovative therapies in China. In addition, she has also participated in drafting and revising several authoritative national guidelines, playing an important role in advancing standardized melanoma care in China.
